Laronidase (Aldurazyme)
Laronidase (Aldurazyme) is a medication used to treat a rare genetic disorder called mucopolysaccharidosis type I (MPS I). MPS I is caused by a deficiency of an enzyme called alpha-L-iduronidase, which is needed to break down complex sugars called glycosaminoglycans (GAGs). When GAGs accumulate in the body, they can cause various symptoms such as organ enlargement, skeletal deformities, vision problems, heart disease, and breathing difficulties.
Laronidase is a synthetic version of the missing enzyme that can help reduce the levels of GAGs and improve the quality of life of people with MPS I. It is given as an intravenous infusion once a week. Laronidase is not a cure for MPS I, but it can slow down the progression of the disease and its complications.
Laronidase was approved by the US Food and Drug Administration (FDA) in 2003 and by the European Medicines Agency (EMA) in 2004. It is marketed under the brand name Aldurazyme by Sanofi Genzyme, a biotechnology company that specializes in rare diseases. Aldurazyme is one of the few treatments available for MPS I and has been shown to be safe and effective in clinical trials.
As a leading exporter of Laronidase (Aldurazyme) based in UAE, we offer high-quality products at competitive prices to our customers worldwide. We have extensive experience in exporting Laronidase (Aldurazyme) to various countries and regions, including Europe, Asia, Africa, and Latin America. We also provide reliable and timely delivery services, as well as professional customer support.
If you are looking for Laronidase (Aldurazyme) for your patients with MPS I, you can trust us to provide you with the best service and product. We have a large inventory of Laronidase (Aldurazyme) in stock and ready to ship. You can order Laronidase (Aldurazyme) from us online or by phone, fax, or email. We accept various payment methods, including credit cards, bank transfers, and PayPal.
To give you an idea of our pricing, we have prepared a table that shows the average price of Laronidase (Aldurazyme) per vial in different countries, based on the latest data from IQVIA MIDAS (a global pharmaceutical market intelligence database). The table also includes the references for each price source. Please note that these prices are subject to change and may vary depending on the exchange rate, taxes, discounts, and other factors.
Laronidase (Aldurazyme) is one of the top five global brands for treating MPS I. The other four are:
- Elosulfase alfa (Vimizim), which is used to treat MPS IVA or Morquio A syndrome. It is manufactured by BioMarin Pharmaceutical and was approved by the FDA in 2014 and by the EMA in 2015.
- Idursulfase (Elaprase), which is used to treat MPS II or Hunter syndrome. It is manufactured by Shire (now part of Takeda) and was approved by the FDA in 2006 and by the EMA in 2007.
- Galsulfase (Naglazyme), which is used to treat MPS VI or Maroteaux-Lamy syndrome. It is manufactured by BioMarin Pharmaceutical and was approved by the FDA in 2005 and by the EMA in 2006.
- Mepolizumab (Nucala), which is used to treat eosinophilic granulomatosis with polyangiitis (EGPA), a rare inflammatory disease that can affect people with MPS. It is manufactured by GlaxoSmithKline and was approved by the FDA in 2017 and by the EMA in 2018.
If you want to learn more about Laronidase (Aldurazyme) or any of these other brands, please contact us today. We will be happy to answer your questions and provide you with more information. We look forward to hearing from you soon.